首页> 美国卫生研究院文献>Oxford Medical Case Reports >Advanced primary nonurachal adenocarcinoma of urinary bladder responding to modified FOLFOX6 and capecitabine: a case report
【2h】

Advanced primary nonurachal adenocarcinoma of urinary bladder responding to modified FOLFOX6 and capecitabine: a case report

机译:改良的FOLFOX6和卡培他滨治疗后进展期晚期原发性膀胱非尿道腺癌1例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Careful morphology and immunohistochemistry study can make an accurate differential diagnosis of primary adenocarcinoma of urinary bladder from metastatic lesions involving bladder, especially cancer arising in colon, but there is yet no consensus regarding the standard chemotherapy for advanced adenocarcinoma of urinary bladder among medical oncologists. Sustained response to modified FOLFOX6 (fluorouracil, oxaliplatin plus leucovorin) regimen and oral capecitabine for multiple metastases in a patient with primary nonurachal adenocarcinoma of urinary bladder is presented here as a strong support that the frontline chemotherapy for this infrequent malignant disease is just like what could be chosen for colorectal cancer.
机译:仔细的形态学和免疫组织化学研究可以从涉及膀胱的转移性病变,特别是结肠癌引起的转移性病变中准确鉴别出原发性膀胱腺癌,但是在医学肿瘤学家之间,对于晚期膀胱腺癌的标准化疗尚无共识。本文提出改良的FOLFOX6(氟尿嘧啶,奥沙利铂加亚叶酸)方案和口服卡培他滨对原发性膀胱非尿道腺癌患者多发转移的持续反应,强烈支持这一罕见恶性疾病的一线化疗就像选择用于大肠癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号